More Sustainable Resources Needed

[February 2010]
Despite the establishment of Product Development Partnerships like DNDi and new commitments from public and private donors, funding for scientific and medical innovation for diseases that disproportionately affect the developing world remains inadequate. DNDi and the George Institute launched in February 2010 a new report on the challenges of registering new drugs for neglected diseases in the African context.

Pfizer and DNDi Advancing International Research Efforts in The Fight Against Neglected Tropical Diseases

[New York, USA, Geneva, Switzerland – November 18, 2009]
Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world. Under the agreement, DNDi will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be developed into new treatments.

Chagas Disease: Break the Silence – Time to Treat

[October 1, 2009]
Santa Monica, California, USA
The Drugs for Neglected Diseases initiative (DNDi) and Doctors Without Borders/Médecins Sans Frontières (MSF) hosted a panel discussion moderated by Univision’s Julio Cesar Ortiz on Chagas disease, a largely ignored infectious disease that kills thousands every year in Latin America. Since its discovery 100 years ago, very little has been done for the millions of people infected with Chagas, including an estimated 300,000 in the US.

Eisai and DNDi Enter into a Collaboration and License Agreement To Develop a New Drug for Chagas Disease

[Geneva, Switzerland – September 29, 2009]
Eisai Co., Ltd. (“Eisai”) and the Drugs for Neglected Diseases initiative (DNDi), a non-profit independent foundation, announced today that they have signed a collaboration and license agreement for the clinical development of a promising new drug for the treatment of Chagas disease, a fatal infectious disease that threatens 100 million people in Latin America and the Caribbean.
[Español] [Português]

Nederlandse overheid kent 14 miljoen euro toe aan DNDi voor de bestrijding van veronachtzaamde tropische ziekten

[Genève, Zwitserland, 3 december, 2010]
Het Nederlandse Ministerie van Buitenlandse Zaken heeft een bedrag van 14 miljoen Euro toegekend aan het Drugs for Neglected Diseases initiative (DNDi) voor de bestrijding van veronachtzaamde tropische ziekten. De subsidie wordt verdeeld over een periode van vier jaar (2011-2014) en vormt een cruciale bijdrage aan de fondsen voor de ‘core disease’-programma’s van DNDi voor Afrikaanse slaapziekte, deziekte van Chagas en Leishmaniase. Dit is de tweede keer dat de Nederlandse overheid een subsidie toekent aan DNDi.
[English]

6th European Congress on Tropical Medicine and International Health (ECTMIH)

[September 6-10, 2009]
Verona, Italy
Drugs for Neglected Diseases initiative (DNDi) and Médecins Sans Frontières (MSF) held a joint workshop at the most important European congress on tropical medicine to discuss the following topic: “Unfinished business on the road to elimination: experiences, needs, and priorities in accessing patients and adequate health tools to treat Chagas disease and sleeping sickness”

XII International Symposium on Epidemiological Control of Diseases Transmitted by Vectors

[September 3-4, 2009]
Buenos Aires, Argentina
The two-day international symposium organized by Mundo Sano Foundation is the biggest scientific meeting on Dengue Fever, Chagas Disease and other neglected diseases in Argentina. Many members of the Argentinean government were present, together with researches and students from several Latin American countries, to discuss and present tools and strategies to fight the challenges related to neglected diseases.

Film and Debate in Amsterdam: global campaign “Wake Up. Time to Treat Chagas Disease!”

[September 2, 2009]
Amsterdam, The Netherlands
The Drugs for Neglected Diseases initiative (DNDi) and the Royal Tropical Institute (KIT) hosted an event to raise awareness for the need for research and development for better health tools and improved access for all Chagas’ patients. The event is part of the global campaign “Wake Up. Time to Treat Chagas Disease!” and brought a panel of experts covering the main aspects of Chagas’ diagnostics, medicines, field treatments etc., and a lively public discussion, chaired by Dr Pieter van Thiel, from the Amsterdam Medical Centre.

 

Time to treat Chagas disease!

[July, 2009]
In July 2009, on the occasion of the Centenary of the discovery of Chagas disease, DNDi launched a campaign to draw attention to the huge gaps in treatments for Chagas patients. ’Research on Neglected Diseases. Time to Treat Chagas Disease!’ brought to light the stark realities surrounding the disease.

The Centenary of Chagas Disease Discovery International Symposium

[July 8-10, 2009]
Rio de Janeiro, Brazil
A three-day international symposium organised by Fiocruz to celebrate the 100 years of Chagas disease discovery by Brazilian researcher, Carlos Chagas, gathered more than 750 international experts. Speakers from five South American countries – together with speakers from France, Canada and the US, including Institut Pasteur, MSF, and DNDi – covered many aspects of Chagas disease: its history, epidemiology, vector control, molecular biology, immunology, and clinical treatment. In parallel to this event, on July 09, DNDi and MSF launched the Chagas Campaign to raise awareness that more is needed to fight the disease: www.treatchagas.org

La organización internacional Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi), el Centro de Investigación en Salud Internacional de Barcelona y la Fundación Clínic para la Investigación Biomèdica aunarán esfuerzos en la investigación para luchar contra la Enfermedad de Chagas

[Ginebra, Suiza/Barcelona, España15 de marzo de 2010]
Hoy tendrá lugar en Barcelona, la firma del convenio de colaboración entre Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi), a través de su Director Ejecutivo el Dr.  Bernard Pècoul, el Centro de Investigación en Salud Internacional de Barcelona (CRESIB, Hospital Clínic-Universidad de Barcelona), a través de su director el Dr. Pedro L. Alonso, y la Fundación Clínic para la Investigación Biomédica (FCRB), a través de su director el Sr. Emili Bargalló.
[English]

Eisai y DNDi firman un contrato de colaboración para desarrollar un nuevo medicamento contra el mal de Chagas

[29 de Septiembre de 2009, Tokio, Japón y Ginebra, Suiza]
Eisai Co., Ltd. (“Eisai”) y la iniciativa Medicamentos para Enfermedades Olvidadas (DNDi, en sus siglas en inglés), una fundación independiente sin fines lucrativos, han anunciado hoy su contrato de colaboración para el desarrollo clínico de un nuevo y prometedor medicamento para el tratamiento de pacientes con mal de Chagas, una enfermedad infecciosa letal que amenaza a 100 millones de personas en América Latina y el Caribe.
[English]
[Português]

Eisai e DNDi iniciam Acordo de Colaboração e Licenciamento para desenvolver novo medicamento contra a doença de Chagas

[29 de setembro de 2009, Tóquio, Japão e Genebra, Suíça]
Eisai Co., Ltd. (“Eisai”) e a iniciativa Medicamentos para Doenças Negligenciadas (DNDi), uma fundação independente sem fins lucrativos, anunciaram hoje a assinatura de um acordo de colaboração para o desenvolvimento clínico de um novo e promissor medicamento para o tratamento de pacientes com a doença de Chagas, uma doença infecciosa fatal que ameaça 100 milhões de pessoas na América Latina e no Caribe.
[English] [Español]

Eisai e DNDi iniciam Acordo de Colaboração e Licenciamento para desenvolver novo medicamento contra a doença de Chagas

[29 de setembro de 2009, Tóquio, Japão e Genebra, Suíça]
Eisai Co., Ltd. (“Eisai”) e a Iniciativa Medicamentos para Doenças Negligenciadas (DNDi), uma fundação independente sem fins lucrativos, anunciaram hoje a assinatura de um acordo de colaboração para o desenvolvimento clínico de um novo e promissor medicamento para o tratamento de pacientes com a doença de Chagas, uma doença infecciosa fatal que ameaça 100 milhões de pessoas na América Latina e no Caribe.
[English] [Español]